These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 16525651)

  • 1. Mutant p53 protein in serum could be used as a molecular marker in human breast cancer.
    Balogh GA; Mailo DA; Corte MM; Roncoroni P; Nardi H; Vincent E; Martinez D; Cafasso ME; Frizza A; Ponce G; Vincent E; Barutta E; Lizarraga P; Lizarraga G; Monti C; Paolillo E; Vincent R; Quatroquio R; Grimi C; Maturi H; Aimale M; Spinsanti C; Montero H; Santiago J; Shulman L; Rivadulla M; Machiavelli M; Salum G; Cuevas MA; Picolini J; Gentili A; Gentili R; Mordoh J
    Int J Oncol; 2006 Apr; 28(4):995-1002. PubMed ID: 16525651
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The relationship between serum p53 autoantibodies and characteristics of human breast cancer.
    Mudenda B; Green JA; Green B; Jenkins JR; Robertson L; Tarunina M; Leinster SJ
    Br J Cancer; 1994 Jun; 69(6):1115-9. PubMed ID: 8198980
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Autoimmunity to the M(r) 32,000 subunit of replication protein A in breast cancer.
    Tomkiel JE; Alansari H; Tang N; Virgin JB; Yang X; VandeVord P; Karvonen RL; Granda JL; Kraut MJ; Ensley JF; Fernández-Madrid F
    Clin Cancer Res; 2002 Mar; 8(3):752-8. PubMed ID: 11895905
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Prognostic significance of p53 autoantibodies in serum of patients with breast carcinoma].
    Huober J; Sprenger H; Costa SD; Zentgraf H; Schmid H; Kaufmann M; Bastert G
    Zentralbl Gynakol; 1996; 118(10):560-4. PubMed ID: 8999710
    [TBL] [Abstract][Full Text] [Related]  

  • 5. p53 mutations are confined to the comedo type ductal carcinoma in situ of the breast. Immunohistochemical and sequencing data.
    O'Malley FP; Vnencak-Jones CL; Dupont WD; Parl F; Manning S; Page DL
    Lab Invest; 1994 Jul; 71(1):67-72. PubMed ID: 8041120
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-p53 in breast cancer: concordance of different assay procedures and association with p53 antigen expression.
    Volkmann M; Sinn HP; Gaugel D; Frey M; Hajjar Y; Ludwig J; Hänsel S; Bastert G; Wallwiener D; Fiehn W; Zentgraf H; Huober J
    Oncology; 2002; 63(3):297-305. PubMed ID: 12381910
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular and immunohistochemical analysis of p53 mutations in scrapings and tissue from preinvasive and invasive breast cancer.
    Lisboa BW; Vogtländer S; Gilster T; Riethdorf L; Milde-Langosch K; Löning T
    Virchows Arch; 1997 Dec; 431(6):375-81. PubMed ID: 9428925
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum p53 autoantibodies in patients with minimal lesions of ductal carcinoma in situ of the breast.
    Regele S; Kohlberger P; Vogl FD; Böhm W; Kreienberg R; Runnebaum IB
    Br J Cancer; 1999 Oct; 81(4):702-4. PubMed ID: 10574259
    [TBL] [Abstract][Full Text] [Related]  

  • 9. p53 alteration in morphologically normal/benign breast tissue in patients with triple-negative high-grade breast carcinomas: breast p53 signature?
    Wang X; Stolla M; Ring BZ; Yang Q; Laughlin TS; Rothberg PG; Skinner K; Hicks DG
    Hum Pathol; 2016 Sep; 55():196-201. PubMed ID: 27246177
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of serum autoantibodies against tumor-associated antigens as biomarkers in lung cancer.
    Li P; Shi JX; Xing MT; Dai LP; Li JT; Zhang JY
    Tumour Biol; 2017 Oct; 39(10):1010428317711662. PubMed ID: 29022480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Deregulation of p53-MDM2 auto-regulatory pathway in breast carcinoma.
    Baliou E; Nonni A; Keramopoulos D; Ragos V; Tsiambas E; Patsouris E; Pavlakis K
    J BUON; 2016; 21(5):1099-1103. PubMed ID: 27837610
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Absence of p53 autoantibodies in sera from glioma patients.
    Rainov NG; Dobberstein KU; Fittkau M; Bahn H; Holzhausen HJ; Gantchev L; Burkert W
    Clin Cancer Res; 1995 Jul; 1(7):775-81. PubMed ID: 9816045
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum p53 auto-antibodies: incidence in familial breast cancer.
    Green JA; Mudenda B; Jenkins J; Leinster SJ; Tarunina M; Green B; Robertson L
    Eur J Cancer; 1994; 30A(5):580-4. PubMed ID: 8080669
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification and validation of new autoantibodies for the diagnosis of DCIS and node negative early-stage breast cancers.
    Lacombe J; Mangé A; Jarlier M; Bascoul-Mollevi C; Rouanet P; Lamy PJ; Maudelonde T; Solassol J
    Int J Cancer; 2013 Mar; 132(5):1105-13. PubMed ID: 22886747
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of p53 auto-antibodies in the sera of breast cancer patients with a new recurrence using an ELISA assay. Does a correlation with the recurrence free interval exist?
    Regidor PA; Regidor M; Callies R; Schindler AE
    Eur J Gynaecol Oncol; 1996; 17(3):192-9. PubMed ID: 8780917
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Significance of the Wild Type p53-Induced Phosphatase 1 Expression in Invasive Breast Cancer.
    Inoue Y; Yamashita N; Kitao H; Tanaka K; Saeki H; Oki E; Oda Y; Tokunaga E; Maehara Y
    Clin Breast Cancer; 2018 Aug; 18(4):e643-e650. PubMed ID: 29275106
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum p53 antibodies in correlation to other biological parameters of breast cancer.
    Sangrajrang S; Arpornwirat W; Cheirsilpa A; Thisuphakorn P; Kalalak A; Sornprom A; Soussi T
    Cancer Detect Prev; 2003; 27(3):182-6. PubMed ID: 12787724
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Humoral immune response to p53 correlates with clinical course in colorectal cancer patients during adjuvant chemotherapy.
    Lechpammer M; Lukac J; Lechpammer S; Kovacević D; Loda M; Kusić Z
    Int J Colorectal Dis; 2004 Mar; 19(2):114-20. PubMed ID: 14634775
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Prognostic significance of p53 expression in patients with mammary gland cancer].
    Shchurov NF; Pogorelaia TIu; Zaplatina SV
    Klin Khir; 2013 Jul; (7):36-8. PubMed ID: 24283043
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers.
    Thor AD; Moore DH II; Edgerton SM; Kawasaki ES; Reihsaus E; Lynch HT; Marcus JN; Schwartz L; Chen LC; Mayall BH
    J Natl Cancer Inst; 1992 Jun; 84(11):845-55. PubMed ID: 1317462
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.